Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 17/20 | 0.37 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | LYN | P07948 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | SIK1 | P57059 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.34 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11909192 | 0.86 | CHEK1 (0.40) | — | |
| SCHEMBL11907769 | 0.84 | MERTK (0.39) | PIM1ABL1CSF1RPRKAG1PRKAA1 | |
| SCHEMBL11909678 | 0.82 | CHEK1 (0.41) | — | |
| SCHEMBL11929499 | 0.80 | CHRM1 (0.43) | PIM1 | |
| SCHEMBL11907420 | 0.80 | CHRM1 (0.43) | PIM1 | |
| SCHEMBL11908837 | 0.77 | SUV39H2 (0.44) | PIM1 | |
| SCHEMBL11908966 | 0.76 | CHRM1 (0.45) | TACR2CNR1 | |
| SCHEMBL12597407 | 0.76 | GSK3B (0.39) | PIM1ABL1CSF1RPRKAG1PRKAA1 | |
| SCHEMBL11908405 | 0.76 | MARK3 (0.40) | PIM1ABL1CSF1RPRKAG1PRKAA1 | |
| SCHEMBL473693 | 0.75 | CHEK1 (0.40) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NPR3, CCNH, CBR3 | PIM1 3366/4885PRKAB2 3324/4885ABL1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.